FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2891817575> ?p ?o ?g. }

• W2891817575 abstract "Tafenoquine is a novel 8-aminoquinoline antimalarial drug recently approved by the U.S. Food and Drug Administration (FDA) for the radical cure of acute Plasmodium vivax malaria, which is the first new treatment in almost 60 years. A population pharmacokinetic (POP PK) analysis was conducted with tafenoquine exposure data obtained following oral administration from 6 clinical studies in phase 1 through phase 3 with a nonlinear mixed effects modeling approach. The impacts of patient demographics, baseline characteristics, and extrinsic factors, such as formulation, were evaluated. Model performance was assessed using techniques such as bootstrapping, visual predictive checks, and external data validation from a phase 3 study not used in model fitting and parameter estimation. Based on the analysis, the systemic pharmacokinetics of tafenoquine were adequately described using a two-compartment model. The final POP PK model included body weight (allometric scaling) on apparent oral and intercompartmental clearance (CL/F and Q/F, respectively), apparent volume of distribution for central and peripheral compartments (V2/F and V3/F, respectively), formulation on systemic bioavailability (F1) and absorption rate constant (Ka ), and health status on apparent volume of distribution. The key tafenoquine population parameter estimates were 2.96 liters/h for CL/F and 915 liters for V2/F in P. vivax-infected subjects. Additionally, the analyses demonstrated no clinically relevant difference in relative bioavailability across the capsule and tablet formulations administered in these clinical studies. In conclusion, a POP PK model for tafenoquine was developed. Clinical trial simulations based on this model supported bridging the exposures across two different formulations. This POP PK model can be applied to aid and perform clinical trial simulations in other scenarios and populations, such as pediatric populations." @default.
• W2891817575 created "2018-09-27" @default.
• W2891817575 creator A5016048999 @default.
• W2891817575 creator A5029531416 @default.
• W2891817575 creator A5037275692 @default.
• W2891817575 creator A5062721744 @default.
• W2891817575 creator A5068237755 @default.
• W2891817575 creator A5076846074 @default.
• W2891817575 date "2018-11-01" @default.
• W2891817575 modified "2023-10-01" @default.
• W2891817575 title "Population Pharmacokinetics of Tafenoquine, a Novel Antimalarial" @default.
• W2891817575 cites W1519586906 @default.
• W2891817575 cites W1572475141 @default.
• W2891817575 cites W1595085242 @default.
• W2891817575 cites W1892471648 @default.
• W2891817575 cites W2037698344 @default.
• W2891817575 cites W2046748446 @default.
• W2891817575 cites W2058734479 @default.
• W2891817575 cites W2087478209 @default.
• W2891817575 cites W2102932191 @default.
• W2891817575 cites W2117767554 @default.
• W2891817575 cites W2120874636 @default.
• W2891817575 cites W2144016867 @default.
• W2891817575 cites W2211322663 @default.
• W2891817575 cites W2528317666 @default.
• W2891817575 cites W2615580270 @default.
• W2891817575 cites W2763343107 @default.
• W2891817575 cites W4230096730 @default.
• W2891817575 cites W4237685485 @default.
• W2891817575 cites W4240219038 @default.
• W2891817575 doi "https://doi.org/10.1128/aac.00711-18" @default.
• W2891817575 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6201082" @default.
• W2891817575 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30201820" @default.
• W2891817575 hasPublicationYear "2018" @default.
• W2891817575 type Work @default.
• W2891817575 sameAs 2891817575 @default.
• W2891817575 citedByCount "16" @default.
• W2891817575 countsByYear W28918175752018 @default.
• W2891817575 countsByYear W28918175752019 @default.
• W2891817575 countsByYear W28918175752020 @default.
• W2891817575 countsByYear W28918175752021 @default.
• W2891817575 countsByYear W28918175752022 @default.
• W2891817575 countsByYear W28918175752023 @default.
• W2891817575 crossrefType "journal-article" @default.
• W2891817575 hasAuthorship W2891817575A5016048999 @default.
• W2891817575 hasAuthorship W2891817575A5029531416 @default.
• W2891817575 hasAuthorship W2891817575A5037275692 @default.
• W2891817575 hasAuthorship W2891817575A5062721744 @default.
• W2891817575 hasAuthorship W2891817575A5068237755 @default.
• W2891817575 hasAuthorship W2891817575A5076846074 @default.
• W2891817575 hasBestOaLocation W28918175751 @default.
• W2891817575 hasConcept C112705442 @default.
• W2891817575 hasConcept C126322002 @default.
• W2891817575 hasConcept C139254425 @default.
• W2891817575 hasConcept C141071460 @default.
• W2891817575 hasConcept C181389837 @default.
• W2891817575 hasConcept C192670549 @default.
• W2891817575 hasConcept C203014093 @default.
• W2891817575 hasConcept C2778048844 @default.
• W2891817575 hasConcept C2778371730 @default.
• W2891817575 hasConcept C2779997623 @default.
• W2891817575 hasConcept C2781413609 @default.
• W2891817575 hasConcept C2908647359 @default.
• W2891817575 hasConcept C31760486 @default.
• W2891817575 hasConcept C535046627 @default.
• W2891817575 hasConcept C71924100 @default.
• W2891817575 hasConcept C98274493 @default.
• W2891817575 hasConcept C99454951 @default.
• W2891817575 hasConceptScore W2891817575C112705442 @default.
• W2891817575 hasConceptScore W2891817575C126322002 @default.
• W2891817575 hasConceptScore W2891817575C139254425 @default.
• W2891817575 hasConceptScore W2891817575C141071460 @default.
• W2891817575 hasConceptScore W2891817575C181389837 @default.
• W2891817575 hasConceptScore W2891817575C192670549 @default.
• W2891817575 hasConceptScore W2891817575C203014093 @default.
• W2891817575 hasConceptScore W2891817575C2778048844 @default.
• W2891817575 hasConceptScore W2891817575C2778371730 @default.
• W2891817575 hasConceptScore W2891817575C2779997623 @default.
• W2891817575 hasConceptScore W2891817575C2781413609 @default.
• W2891817575 hasConceptScore W2891817575C2908647359 @default.
• W2891817575 hasConceptScore W2891817575C31760486 @default.
• W2891817575 hasConceptScore W2891817575C535046627 @default.
• W2891817575 hasConceptScore W2891817575C71924100 @default.
• W2891817575 hasConceptScore W2891817575C98274493 @default.
• W2891817575 hasConceptScore W2891817575C99454951 @default.
• W2891817575 hasFunder F4320307773 @default.
• W2891817575 hasFunder F4320322413 @default.
• W2891817575 hasIssue "11" @default.
• W2891817575 hasLocation W28918175751 @default.
• W2891817575 hasLocation W28918175752 @default.
• W2891817575 hasLocation W28918175753 @default.
• W2891817575 hasLocation W28918175754 @default.
• W2891817575 hasOpenAccess W2891817575 @default.
• W2891817575 hasPrimaryLocation W28918175751 @default.
• W2891817575 hasRelatedWork W2005031996 @default.
• W2891817575 hasRelatedWork W2020343058 @default.
• W2891817575 hasRelatedWork W2047596343 @default.
• W2891817575 hasRelatedWork W2067978064 @default.
• W2891817575 hasRelatedWork W2075090459 @default.
• W2891817575 hasRelatedWork W2086460393 @default.

• next